Chandigarh Herald

Diabetes Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Diabetes Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

April 12
18:15 2023
Diabetes Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Diabetes Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diabetes pipeline constitutes 200+ key companies continuously working towards developing 200+ Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Diabetes Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetes Market.

The Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To know more about the Diabetes Pipeline report offerings, click here @ Diabetes Pipeline Assessment

 

Some of the key takeaways from the Diabetes Pipeline Report:

  • Diabetes Companies across the globe are diligently working toward developing novel Diabetes treatment therapies with a considerable amount of success over the years. 
  • Diabetes companies working in the treatment market are Scohia Pharma, Eli Lilly and Company, Oramed, Genexine, Carmot Therapeutics, Dompe Farmaceutici, REMD Biotherapeutics, Precigen Inc, Yabao Pharmaceutical Group, Daewoong Pharmaceutical, AstraZeneca, BTB Pharma, Jiangsu Hengrui Medicine, CSPC ZhongQi Pharmaceutical Technology, Tolerion, Caladrius Biosciences, Imcyse SA, Adocia, Innovent Biologics, Neuraly, Inc., Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group, OPKO Health, Novartis, Pfizer,  vTv Therapeutics, Xeris Pharmaceuticals, PegBio Co., Akros Pharma, Lexicon Pharmaceuticals, Anelixis Therapeutics, Diasome Pharmaceuticals, Ionis Pharmaceuticals, Melior Pharmaceuticals, Chong Kun Dang, Arecor, Biocon and others, are developing therapies for the Diabetes treatment 
  • Emerging Diabetes therapies such as TRC150094, DBPR108, ORMD-0801, LY3298176, Cotadutide, BTB002, IMCY-0098, ADO09, IBI362, BTI320, NLY01, insulin 338, SY-004, BI 456906, TQ-F3083, OPK-88003, CFZ533, PF-06882961, HS-20004, TTP273, PRAM9, PB-119, SCO-094, Tirzepatide , LY-3502970, ORMD-0801 , GX G6 , CT-388 , Ladarixin, Volagidemab, AG019, SY-004, Enavogliflozin, Cotadutide, BTB002, INS068, DBPR108, TOL-3021, CLBS03, ISIS-GCGRRx, MLR-1023, JTT-662, CKD-393, AT278 and others., are expected to have a significant impact on the Diabetes market in the coming years.   
  • In December 2019, University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk announced that they have entered into a five-year research collaboration where they will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes.

 

Diabetes Overview

Diabetes is a disease that occurs when the blood glucose, also called blood sugar, gets too high. Different types of Diabetes are: Type 1 Diabetes, which is an autoimmune disease, affects about 10 percent of total people with Diabetes. Type 2 Diabetes occurs when a person becomes insulin-resistant. Pre-Diabetes occurs when blood sugar is higher than normal, but it’s not high enough for a diagnosis of type 2 Diabetes.

 

Get a Free Sample PDF Report to know more about Diabetes Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight

 

Emerging Diabetes Drugs Under Different Phases of Clinical Development Include:

  • SCO-094: Scohia Pharma
  • Tirzepatide: Eli Lilly and Company
  • LY-3502970: Eli Lilly and Company
  • ORMD-0801: Oramed
  • GX G6: Genexine
  • CT-388: Carmot Therapeutics
  • Ladarixin: Dompe Farmaceutici
  • Volagidemab: REMD Biotherapeutics
  • AG019: Precigen Inc
  • SY-004: Yabao Pharmaceutical Group
  • Enavogliflozin: Daewoong Pharmaceutical
  • Cotadutide: AstraZeneca
  • BTB002: BTB Pharma
  • INS068: Jiangsu Hengrui Medicine
  • DBPR108: CSPC ZhongQi Pharmaceutical Technology 

 

Diabetes Pipeline Therapeutics Assessment

  • Diabetes Assessment by Product Type
  • Diabetes By Stage and Product Type
  • Diabetes Assessment by Route of Administration
  • Diabetes By Stage and Route of Administration
  • Diabetes Assessment by Molecule Type
  • Diabetes by Stage and Molecule Type

 

DelveInsight’s Diabetes Report covers around 4+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Diabetes product details are provided in the report. Download the Diabetes pipeline report to learn more about the emerging Diabetes therapies- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight

 

Diabetes Pipeline Analysis:

The Diabetes pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
  • Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market.

 

Download Sample PDF Report to know more about Diabetes drugs and therapies- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight

  

Scope of Diabetes Pipeline Drug Insight    

  • Coverage: Global
  • Key Diabetes Companies: Scohia Pharma, Eli Lilly and Company, Oramed, Genexine, Carmot Therapeutics, Dompe Farmaceutici, REMD Biotherapeutics, Precigen Inc, Yabao Pharmaceutical Group, Daewoong Pharmaceutical, AstraZeneca, BTB Pharma, Jiangsu Hengrui Medicine, CSPC ZhongQi Pharmaceutical Technology, Tolerion, Caladrius Biosciences, Imcyse SA, Adocia, Innovent Biologics, Neuraly, Inc., Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group, OPKO Health, Novartis, Pfizer,  vTv Therapeutics, Xeris Pharmaceuticals, PegBio Co., Akros Pharma, Lexicon Pharmaceuticals, Anelixis Therapeutics, Diasome Pharmaceuticals, Ionis Pharmaceuticals, Melior Pharmaceuticals, Chong Kun Dang, Arecor, Biocon and others
  • Key Diabetes Therapies: TRC150094, DBPR108, ORMD-0801, LY3298176, Cotadutide, BTB002, IMCY-0098, ADO09, IBI362, BTI320, NLY01, insulin 338, SY-004, BI 456906, TQ-F3083, OPK-88003, CFZ533, PF-06882961, HS-20004, TTP273, PRAM9, PB-119, SCO-094, Tirzepatide , LY-3502970, ORMD-0801 , GX G6 , CT-388 , Ladarixin, Volagidemab, AG019, SY-004, Enavogliflozin, Cotadutide, BTB002, INS068, DBPR108, TOL-3021, CLBS03, ISIS-GCGRRx, MLR-1023, JTT-662, CKD-393, AT278 and others
  • Diabetes Therapeutic Assessment: Diabetes current marketed and Diabetes emerging therapies
  • Diabetes Market Dynamics: Diabetes market drivers and Diabetes market barriers 

 

Request for Sample PDF Report for Diabetes Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/diabetes-pipeline-insight

 

Table of Contents

1

Diabetes Report Introduction

2

Diabetes Executive Summary

3

Diabetes Overview

4

Diabetes- Analytical Perspective In-depth Commercial Assessment

5

Diabetes Pipeline Therapeutics

6

Diabetes Late Stage Products (Phase II/III)

7

Diabetes Mid Stage Products (Phase II)

8

Diabetes Early Stage Products (Phase I)

9

Diabetes Preclinical Stage Products

10

Diabetes Therapeutics Assessment

11

Diabetes Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Diabetes Key Companies

14

Diabetes Key Products

15

Diabetes Unmet Needs

16 

Diabetes Market Drivers and Barriers

17

Diabetes Future Perspectives and Conclusion

18

Diabetes Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting